The Syncona Foundation announces £301,500 donation to Generating Genius

The Syncona Foundation today announced a donation of £301,500 over three years to charity Generating Genius, becoming their largest scholarship funder.

Autolus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference being held virtually from March 9-10, 2021.

Freeline Announces Expansion of Executive Leadership

Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments. Chief Financial Officer Brian M. Silver leaving Freeline to pursue a new opportunity

Introduction to Richard Francis, Chief Executive of Purespring Therapeutics

Richard Francis discusses why he has taken on the role of CEO at PureSpring Therapeutics, the importance of Syncona’s role (and expertise in the AAV gene therapy field), and the unique opportunity PureSpring has to make a difference to millions of people as it seeks to develop transformational treatments for patients in areas of high unmet need.

Introduction from Quell Therapeutics, CEO, Iain McGill

Iain McGill introduces Quell Therapeutics, a leader in the new field of T-regulatory cells, and announces their planned expansion to their series A by Syncona making it the largest Series A in the space. Iain discusses Quell’s progress to date and what the financing will enable Quell to achieve

Syncona's Martin Murphy and Freddie Dear: Quell Series A expansion

Martin Murphy and Freddie Dear explain why Syncona has expanded Quell’s financing to support the additional pipeline programmes, how they have worked with the Quell team, and their ambition for the company to become a global leader in treating liver transplantation, autoimmune and inflammatory diseases.

Quell: the science and the unmet medical need for patients

Marc Martinez-Llordella, VP Biology at Quell, discusses why liver transplantation is the first programme Quell Therapeutics has selected for entry to the clinic and the advantages of engineered Tregs. Nathalie Belmonte, SVP Research and Translation, discusses Quell’s objective of making a complete cure for liver transplant patients through Tregs, leading to an improvement in patients quality of life and survival. Nathalie also discusses Quell’s new research programmes targeting ALS and Type 1 diabetes

Autolus Announces Proposed Public Offering in the United States

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of up to $100 million of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share. All ADSs to be sold in the proposed offering will be offered by Autolus. Autolus also intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of ADSs at the public offering price, on the same terms and conditions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or the actual size or terms of the offering.

Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium™

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that it will deliver one oral and three e-poster presentations at the 17TH Annual WORLDSymposium™ taking place virtually from February 8 – 12, 2021, highlighting data from its gene therapy programs in Gaucher and Fabry diseases.

Autolus Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on March 4

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2020 financial results and operational highlights before open of U.S. markets on Thursday, March 4, 2021.

Neogene Therapeutics Announces Ton Schumacher, Ph.D., Company Co-Founder, Awarded 2021 Jeantet-Collen Prize for Translational Medicine

Renowned immunologist and T cell engineering expert awarded distinguished prize for conducting fundamental translational research of substantial significance for medicine

Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium 2021

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that it will present two e-posters at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) taking place 3-5 February 2021.

SwanBio Therapeutics Appoints Alison Lawton to Board of Directors

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointment of Alison Lawton to the company’s Board of Directors.

Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager

Achilles Therapeutics (“Achilles” or the “Company”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Arjan Roozen as VP, Site Head and General Manager, with responsibility for scaling up Achilles’ manufacturing operations to supply cell therapy products for late-stage clinical studies and commercial supply.

Purespring appoints new Chief Executive Officer

Purespring Therapeutics (Purespring), a kidney-focused AAV gene therapy company, announces that it is intended to appoint Richard Francis as Chief Executive Officer following the completion of its Series A financing of £45.0 million, from 1 February 2021.

Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference

Achilles Therapeutics to present at the 39th Annual J.P. Morgan Healthcare Conference

Autolus Therapeutics provides business outlook for 2021 & 2022

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an updated business outlook, strengthening its focus on its potentially transformational CAR T cell therapy candidate, AUTO1, which is being investigated in relapsed / refractory adult B-Acute Lymphoblastic Leukemia (ALL).

SwanBio Therapeutics Appoints Scott McMillan, Ph.D., as Chief Technical Officer

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced that Scott McMillan, Ph.D., has been appointed Chief Technical Officer.

Freeline to participate at Conferences during January 2021

Freeline Therapeutics Holdings plc (Nasdaq: FRLN), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced they will participate virtually at conferences during January 2021.

Autolus Therapeutics to participate in Investor Conferences through January 2021

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in investor conferences through January 2021.

Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases

Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead to permanent vision loss. Gyroscope has an exclusive option to the intellectual property associated with, and arising from, the research conducted under the agreement.

Achilles Therapeutics Appoints Lee M. Stern as VP, IR & External Communications

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours today announced the appointment of Lee M. Stern as VP, IR & External Communications where he will lead investor and financial communications activities.

Gyroscope Therapeutics Announces Appointments of Industry Veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to its Board of Directors

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that Jennifer Cook, David Fellows, and Renée Galá have been appointed to the Gyroscope Board of Directors, effective immediately.

Resolution Therapeutics Announces a £26.6m Series A Financing from Syncona Ltd

Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases characterised by life-threatening inflammatory organ damage, today announced completion of a £26.6m Series A financing from Syncona Ltd (“Syncona”). Syncona entered into a collaboration with the University of Edinburgh Centre for Regenerative Medicine in 2018 which has provided the foundation of Resolution’s technology platform. The Series A funding is expected to deliver early clinical data for the company’s first product.

Introducing Resolution Therapeutics

A new Syncona company exploiting the wound healing ability of macrophages to stimulate organ repair following severe injury as a result of chronic disease. Syncona Partners, Ed Hodgkin and Gonzalo Garcia, discuss founding this new company.

Achilles Therapeutics Appoints Robert Coutts as Chief Financial Officer

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Robert Coutts as Chief Financial Officer. Robert has served as Finance Director at Achilles since the Company’s formation in 2017.

Autolus Therapeutics announces publication of new AUTO6 Phase 1 data in childhood neuroblastoma in Science Translational Medicine

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announces publication of AUTO6 (1RG-CAR T) Phase 1 data in Science Translational Medicine. AUTO6 is a second generation GD2-targeting CAR T candidate, developed in collaboration with UCL, and the trial was sponsored and run by Cancer Research UK’s Centre for Drug Development.

SwanBio Therapeutics Expands Board of Directors with Appointments of Proven Industry Leaders

SwanBio Therapeutics (SwanBio), a gene therapy company advancing AAV-based therapies for the treatment of devastating, genetically defined neurological conditions, today announced the appointments of Patricia “Patty” Allen, former Chief Financial Officer of Zafgen, Inc.; Danny Bar-Zohar, M.D., Global Head of Development at Merck KGaA; and Alex Hamilton, Ph.D., Partner at Syncona, to the company’s Board of Directors. In addition to her role as a non-executive Director, Ms. Allen will serve as the Chair of SwanBio’s Audit Committee.

Syncona founds Purespring with a £45m Series A Financing

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the foundation of a new Syncona company, Purespring Therapeutics (Purespring), with a £45.0 million Series A financing. Syncona’s holding value in Purespring is £3.9 million following the investment of the first tranche of the Series A commitment and, at the point all current commitments are invested, Syncona will have an 84 per cent stake in the business.

Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours

Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubscribed Series C financing. OrbiMed, Boxer Capital of Tavistock Group, and other prominent US-based, healthcare-focused institutional investors join existing investors including RA Capital, Syncona, Forbion, Invus, Perceptive Advisors and Redmile Group.

Introduction to Purespring

Watch Syncona Partner, Dominic Schmidt discuss how we sourced and founded our new kidney gene therapy company, Purespring

Freeline to present at the 3rd Annual Evercore ISI Health CONx Conference

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that management will participate in a fireside chat at the 3rd Annual Evercore ISI Health CONx Conference on 3 December, 2020 from 08.00 – 8.20 am ET.

Autolus Therapeutics to host Investor Conference Call to discuss AUTO1 and AUTO3 data presented at ASH and to participate in the Jefferies Virtual London Healthcare Conference

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference:

Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of the Phase II HORIZON trial evaluating GT005 in people with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The first patient to receive GT005 in HORIZON was enrolled and dosed in the United States by Jeffrey Heier, M.D., at Ophthalmic Consultants of Boston. HORIZON is a randomised controlled Phase II trial evaluating the safety and effectiveness of GT005 in a broad population of people with GA secondary to dry AMD. GT005 is an investigational one-time AAV-based gene therapy that is designed to restore balance to an overactive complement system by increasing production of the Complement Factor I (CFI) protein, and is intended to slow the progression of GA that can lead to blindness.

Achilles Therapeutics Announces Grant of European Patent Covering Use of Selectively Expanded T cells Targeting Clonal Neoantigens for the Treatment of Cancer

Achilles Therapeutics Limited (“Achilles”), a clinical-stage biopharmaceutical company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the decision by the European Patent Office (“EPO”) to grant European patent EP3288581B, which covers the treatment of cancer using T cells that have been selectively expanded to target clonal neoantigens.

Anaveon announces presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Anaveon, an immuno-oncology company, today announced that it will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.

Autolus Therapeutics Reports Third Quarter 2020 Financial Results and Operational Progress

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2020.

Freeline appoints Mark Baldry as Chief Commercial Officer

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced that Mark Baldry, MBA, has today been appointed as the Company’s new Chief Commercial Officer, effective from today’s date.

Freeline Reports Half Year 2020 Financial Results and Recent Business Highlights

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, liver directed, AAV-based gene therapy company today announced its financial results for the first half of 2020 and provided a business update.

Freeline to present new data at the 12th Annual Protein and Antibody Engineering Summit

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced new data on analytical technologies for determining the proportion of Adeno-associated viruses (AAV) capsids containing full-length vector genomes will be presented at the 12th Annual Protein and Antibody Engineering Summit (PEGS), 9 – 13 November 2020.

Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the first surgery using its proprietary OrbitTM Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been conducted in the ongoing Phase I/II FOCUS trial. The surgery was conducted in the United States by Jeffrey Heier, M.D., at Ophthalmic Consultants of Boston.

Quell Therapeutics Enters a Collaborative Research Agreement with the University of Sheffield

Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with the Sheffield Institute for Translational Neuroscience (SITraN), an international centre of excellence within the University of Sheffield recognised for its ground-breaking work in the fight against neurodegenerative disorders. Under the terms of the agreement, Quell Therapeutics will collaborate in a joint research programme with SITraN to accelerate the validation of Quell’s engineered Treg cell therapy platform for use in the treatment of neuroinflammatory diseases.

Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Neogene Therapeutics, Inc., a biotechnology company pioneering a new class of fully personalized T cell therapies to treat cancer, today announced a broad strategic partnership. The companies will leverage Neogene’s proprietary expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells due to cancer-associated DNA mutations, together with Twist’s DNA synthesis platform and product lines to develop personalized chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies for patients with cancer.

Achilles Therapeutics appoints Professor Karl Peggs as Chief Medical Officer

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the appointment of Professor Karl Peggs as Chief Medical Officer (CMO) with effect from 4th January 2021. Professor Peggs is an internationally recognised leader in the field of cancer immunology and a founder of the Company.

Neogene Therapeutics Appoints Former Roche Chairman and Chief Executive Officer Franz B. Humer, Ph.D., as Executive Chairman of Board of Directors

Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced the appointment of Franz B. Humer, Ph.D., as Executive Chairman of the Board of Directors. A world-renowned pharmaceutical industry trailblazer, Dr. Humer served as Chairman and Chief Executive Officer of Roche Holding, Ltd. over a period of 16 years before retiring in 2014. As a result of the recent Series A financing, Rachel Mears of Jeito Capital, Elisa Petris, Ph.D., of Syncona Investment Management Ltd., Caroline Stout of EcoR1 Capital, and Katherine Wood of TPG Capital, also have joined the Neogene Board.

Freeline announces promotion of Romuald Corbau, Ph.D. to Chief Scientific Officer (3)

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces that Romuald Corbau, Ph.D. has been promoted to the role of Chief Scientific Officer. The Founder of Freeline, Professor Amit Nathwani, will continue in his role as Clinical and Scientific Adviser and member of the Board of Directors of the Company.

Freeline announces supply agreement for haemophilia B program

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announces their supply agreement with Thermo Fisher Scientific Inc. (“Thermo Fisher”).

Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration (1)

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is an investigational one-time AAV-based gene therapy that is delivered under the retina and is intended to slow the progression of GA that can lead to blindness.

Neogene Therapeutics Raises $110 Million Series A Financing to Develop Next-Generation Fully Personalized Neo-Antigen T Cell Receptor (TCR) Therapies

Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, today announced that it has raised $110 million in a Series A financing. The financing was co-led by EcoR1 Capital, Jeito Capital and Syncona, with participation from Polaris Partners and Pontifax. Seed investors Vida Ventures, TPG and Two River also participated in the round.

Gyroscope Therapeutics Announces Appointment of Sean Bohen to the Board of Directors (1)

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that biotech industry veteran Sean Bohen, M.D., Ph.D., has been appointed to the Gyroscope Board of Directors, effective immediately. Dr. Bohen will also serve as Chair of the Board’s Research and Development Committee. Dr. Bohen brings more than 30 years of experience in the discovery and development of new medicines. Over the course of his career, he has made significant contributions to the early- and late-stage development of numerous FDA-approved drugs.

Freeline to participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that Theresa Heggie, Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference on September 15 at 8.00 am EDT.

Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO3 data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and to participate in Banking conferences through September

Gyroscope Therapeutics Announces FDA Clearance for Orbit Subretinal Delivery System

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that the U.S. Food & Drug Administration (FDA) has granted 510(k) clearance for the Orbit™ Subretinal Delivery System (Orbit SDS). The Orbit SDS is indicated for microinjection into the subretinal space at the back of the eye. The microinjection procedure is designed to avoid damaging the structure of the eye by preventing the need for a vitrectomy, a procedure that involves removing the vitreous (the gel-like substance that fills the eye). The approach also eliminates the need to create a retinotomy (a hole in the retina) in order to access the subretinal space. This clearance is based on injection of Balanced Salt Solution (BSS) or BSS PLUS®.*

Gyroscope Therapeutics Announces Initiation of Phase II Programme Evaluating its Investigational Gene Therapy, GT005, for Dry Age-Related Macular Degeneration

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the initiation of its Phase II programme evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). Dry AMD is a leading cause of permanent vision loss in people over the age of 50. GT005 is a one-time AAV-based gene therapy that is delivered under the retina. The goal of the Phase II clinical trial programme is to determine if GT005 has the potential to slow the progression of GA.

Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to its Clinical and Scientific Advisory Boards

Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced the appointment of leading experts in retinal disease, gene therapy and the complement system to its Clinical and Scientific Advisory Boards. The newly appointed boards will help guide the development of the company's lead investigational gene therapy, GT005, a one-time therapy being developed to potentially slow the progression of dry age-related macular degeneration (AMD), as well as novel gene therapy delivery systems and additional pipeline candidates.

Autolus announces changes to its Board and Management Team

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the appointment of Dr. Jay T Backstrom to its Board of Directors, effective August 1, 2020.

Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, August 6, 2020.

OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director

OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical technologies to drive drug discovery in high definition, today announced the appointment of Dr Nathalie Franchimont as a Non-Executive Director. Nathalie brings more than 15 years of leadership experience in biotechnology and pharma industries.

Freeline files registration statement for proposed initial public offering in the United States

Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.

Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting

Freeline, a clinical stage, Adeno-Associated Virus (AAV) based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced new data on its AAV gene therapy product candidate, FLT180a, in severe Haemophilia B patients at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress. The data presented in an oral presentation by Professor Pratima Chowdary of the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital UK and UCL Cancer Institute, and Principal Investigator for the study, demonstrated with data up to two years for the earliest cohort, that a dose of between 7.5e11 and 9.75e11 vg/kg has the potential to create durable Factor IX (FIX) activity levels in the normal range in patients with severe Haemophilia B.

Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that it has appointed Daniel Hood as Chief Legal Officer. Dan is a highly experienced lawyer with more than 13 years’ experience working in-house within the pharmaceutical and life sciences sector which follows 10 years in private practice.

Freeline Closes $120 Million Series C Financing Round

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million extended Series C financing. The financing augments Syncona’s previously announced Series C investment in Freeline of $40 million (£30.6 million) with an additional $80 million (£61.2 million) of new capital. The round was led by Novo Holdings A/S, Eventide Asset Management and Wellington Management Company, with additional participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.

Freeline Announces Additional Financing Plans

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States. The timing and the terms of any such additional capital raising have not yet been determined and are subject to market conditions and other factors. There is no assurance that any such additional capital raising will be completed.

Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that Professor Pratima Chowdary of the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital UK and UCL Cancer Institute, and Chief investigator for the study, will present data in a late-breaking abstract session at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on behalf of co-authors, which will be held virtually 12-14 July 2020. In addition, Freeline has five posters at the conference and will be presenting data on the Factor IX Padua variant and health economics from its Adeno-Associated Virus (AAV)-based haemophilia gene therapy platform.

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell (cNeT) therapy in patients with advanced non-small cell lung cancer (NSCLC). In May 2020, Achilles dosed the first patient with cNeT in its Phase I/II THETIS study in recurrent or metastatic malignant melanoma.

Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting

Conference Call and Webcast to be held Thursday, June 25, 2020 at 8:30 AM EDT / 1:30 PM BST Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced preclinical data related to AUTO5 in T cell lymphoma and AUTO6NG in small cell lung cancer, as well as an oral presentation related to AUTO7 in prostate cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22 - 24, 2020.

Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on its AUTO1 program, the company’s CAR T cell therapy being investigated in the ongoing ALLCAR Phase 1 study of relapsed / refractory adult B-Acute Lymphocytic Leukemia (ALL), at the European Hematology Association EHA25 Virtual Congress beginning June 11.

Syncona FY20: Martin Murphy discusses FY20 results

Syncona FY20: Martin Murphy discusses the impact of COVID-19

Syncona FY20: Martin Murphy discusses the outlook for Syncona

Quell Therapeutics strengthens its Board with the appointments of Dr Dhaval Patel and Sir Robert Lechler and hires Dr Natalie Belmonte as SVP Research & Translation

Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the appointments of seasoned industry expert, Dr Dhaval Patel, Executive Vice President and Chief Scientific Officer UCB S.A. (Brussels, Belgium), and Senior Clinical Academic, Professor Sir Robert Lechler, Senior Vice President/Provost (Health) and Executive Director of King's Health Partners Academic Health Sciences Centre, to its Board of Directors.

Autolus Therapeutics reschedules its investor EHA conference call

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has rescheduled its investor conference call to discuss data at the European Hematology Association EHA25 Virtual Congress to 12 June 2020 at 7.30 am EDT, 12.30 pm BST. This call was previously announced and scheduled for 15 June 2020.

SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer

SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of adrenomyeloneuropathy (AMN) and other neurological diseases, today announced the appointment of Steven Zelenkofske, D.O., M.S. as chief medical officer (CMO). Dr. Zelenkofske brings more than 20 years of experience to the SwanBio Therapeutics team, most recently serving as the CMO at Achillion Pharmaceuticals, a clinical stage company focused on complement inhibitors, and at UniQure, a clinical stage gene therapy company focused on genetic diseases.

Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL), during the Annual Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program beginning May 29.

Achilles Doses First Patient

Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells. This marks a significant milestone for Achilles, delivering the first precision TIL therapy

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens (1)

Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that it has dosed the first patient in a Phase I/II study of a clonal neoantigen T cell (cNeT) therapy in patients with recurrent or metastatic malignant melanoma. This is the first tumour-infiltrating lymphocyte (TIL) therapy to enter clinical trials where the TILs have been specifically selected to target clonal neoantigens – antigens which are believed to be present on all tumour cells.

Autolus Therapeutics to host Investor Conference Calls through June (4)

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host investor conference calls through June.

Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted notice of its Annual General Meeting (AGM) to shareholders (the "Notice"), which can be viewed and downloaded from www.autolus.com. The Notice states that the AGM is scheduled to be held at Autolus headquarters in White City at 1.00 pm BST (8.00 am EDT) on Thursday, June 18, 2020.

Autolus Therapeutics to Present New Data at the Virtual 2020 AACR Annual Meeting

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced poster presentations related to AUTO5 in T cell lymphoma and AUTO6NG in small cell lung cancer, as well as an oral presentation related to AUTO7 in prostate cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on Jun 22 - 24, 2020.

Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced presentations related to its AUTO1 and AUTO3 programs, the company’s CAR T cell therapies being investigated in Phase 1/2 studies of adult Acute Lymphocytic Leukemia (ALL) and relapsed/refractory Diffuse Large B Cell Lymphoma (DLBCL), respectively, at the European Hematology Association EHA25 Virtual Congress on June 11 – 14, 2020. The AUTO1 data to be presented will expand on the positive data presented at the American Society of Hematology (ASH) in December 2019 with additional patients as well as longer term data on previously treated patients.

OMass Announces Publication in Nature Methods

OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, announces the publication of a novel, highly enabling native mass spectrometry approach that marks a significant technical advance in the field. In this study OMass scientists, in collaboration with researchers from Oxford University, the Karolinska Institute and Thermo Fisher Scientific, describe the development of a top-down mass spec methodology. The development allows definition of the lipidome/metabolome in contact with the protein complex of interest and was supported by MD simulations carried out at the University of Southampton. The development of the new tribrid Orbitrap MS instrument was the result of OMass and Oxford university scientists working closely with a team at Thermo Fisher Scientific. The article was published in the 5th May 2020 print issue of Nature Methods

Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced an oral presentation related to its AUTO3 program, the company’s CAR T cell therapy being investigated in the Alexander study, a Phase 1/2 study in relapsed/refractory diffuse large B cell lymphoma (DLBCL), during the Annual Society of Clinical Oncology 2020 (ASCO20) Virtual Scientific Program beginning May 29. The data to be presented will expand on the positive data presented at the EHA-EBMT 2nd European CAR T Cell Meeting in January 2020.

Gene Therapy Explained

An animation explaining what gene therapy is, how it has evolved over 50 years and the goal of providing a long-term cure for patients who receive treatment.

Achilles Therapeutics announces formation of Scientific Advisory Board

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumor target, today announced the formation of a Scientific Advisory Board (SAB) with three world-renowned appointments: Dr Elizabeth M. Jaffee, Dr Scott Antonia and Dr Christopher A. Klebanoff. The SAB will work closely with Achilles’ senior management team and Founders to advance the Company’s pipeline of solid tumor cancer therapies.

Autolus Therapeutics Reports First Quarter 2020 Financial Results and Operational Progress

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its financial and operational results for the first quarter ended March 31, 2020.

Freeline receives Orphan Drug Designation from the FDA for FLT190 for the treatment of Fabry Disease

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation for FLT190 for the treatment of Fabry Disease. This comes soon after Freeline announced it had received Orphan Drug Designation for FLT190 from the European Commission, based on a positive opinion from the Committee for Orphan Medicinal Products of the European Medicines Agency.

Autolus Therapeutics to Report First Quarter 2020 Financial Results and Host Conference Call on May 7

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its first quarter 2020 financial results and operational highlights before open of U.S. markets on Thursday, May 7, 2020.

Danny Bar-Zohar joins Syncona as Partner

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, announces the appointment of Danny Bar-Zohar, M.D., as Syncona Partner, from 17 April 2020. In this role, Danny will leverage his expertise in clinical development, regulatory environments and medical affairs to help Syncona further build and establish its portfolio of life science companies.

Freeline to present data on its AAV gene therapy platform and programmes at the 23rd annual American Society of Gene & Cell Therapy 2020 (3)

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces it will present four abstracts at the 23rd annual American Society of Gene & Cell Therapy (ASGCT) meeting on 12-15 May, 2020. Due to the ongoing COVID-19 pandemic, the organisers, in consultation with relevant authorities, have announced that this year’s ASGCT meeting will be held virtually.

SwanBio Therapeutics Announces Series A Expansion to Fund its Lead Program and Grow Pipeline in Gene Therapy for Neurological Diseases

SwanBio Therapeutics, a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of AMN and other neurological diseases, today announces the successful completion of a $52 million expanded Series A financing.

Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced that it will present a manufacturing update using the VELOSTM manufacturing platform for its lead programs at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting.

Quell Therapeutics Enters a Collaborative Research Agreement with the Hannover Medical School

London and Hannover – April 7 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative research agreement with Hannover Medical School (MHH). Under the terms of the agreement, Quell Therapeutics will collaborate in joint research with MHH to accelerate the discovery and validation of multiple Chimeric Antigen Receptor (CAR)-Treg cell therapies.

Achilles Therapeutics appoints Carsten Boess to the Board of Directors

Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced the appointment of Carsten Boess as Non-Executive Director to its Board, effective 1 April 2020.

COVID-19: Syncona Business Update

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, today provides an update on its business following the outbreak of the COVID-19 pandemic.

Freeline appoints Julie Krop M.D. as Chief Medical Officer (2)

- Experienced clinical leader with extensive experience in guiding rare disease therapies to registration - London, 23 March, 2020 – Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the appointment of Julie Krop M.D., as Chief Medical Officer (CMO) effective 1 April, 2020.

Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer

Achilles Therapeutics (“Achilles”), a clinical stage oncology company developing personalised cell therapies targeting clonal neoantigens (a novel class of tumour target), today announced the appointment of Professor Sergio Quezada as Chief Scientific Officer (CSO) with effect from 6 April 2020.

Freeline receives Orphan Drug Designation from the European Commission for FLT190 for the treatment of Fabry Disease

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces that the European Commission (EC) has granted orphan drug designation for FLT190 for the treatment of Fabry Disease, based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).

Autolus Therapeutics to Present at the Cowen 40th Annual Health Care Conference

LONDON, February 25, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr. Christian Itin, chairman and chief executive officer, will present at the Cowen 40th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at 10.00 am ET. The company will also host one-on-one meetings with attendees.

OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences

OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, today announced completion of the acquisition of assets and capabilities from Excellerate Biosciences (“Excellerate”), including a team of experienced pharmacologists led by Professor Steven Charlton.

Autolus Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on March 3 (1)

LONDON, UK, February 24, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its fourth quarter and full year 2019 financial results and operational highlights before open of U.S. markets on Tuesday, March 3, 2020.

OMass Therapeutics Announces £27.5 Million Extended Series A Financing

- Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders - Oxford, 17 February 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high definition, today announced completion of an extended Series A financing of £27.5 million from existing investors Syncona Ltd (“Syncona”) and Oxford Sciences Innovation (“OSI”) who contributed £16.6 million and £10.4 million respectively. They were joined in the round with £0.5 million from the University of Oxford. This comes after an initial Series A investment of £14 million in 2018 bringing the total series A to £41.5 million.

Gyroscope Therapeutics strengthens leadership team ahead of next stage of company growth

Gyroscope Therapeutics, a company developing gene therapies and surgical delivery systems for retinal diseases, announces the strengthening of its leadership team with the hiring of Dr. Nadia Waheed from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO) and the promotion of Dr. Jane Hughes, formerly VP Translational Research, to Chief Scientific Officer (CSO).

Freeline Data Update in Haemophilia B

Freeline Data Update at EAHAD conference 7 Feb 2020 – watch our video overview

Freeline to present data on AAV-based gene therapies for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium™ 2020

Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announces it will present data on its gene therapy programmes for Fabry Disease and Gaucher Disease at the 16th annual WORLDSymposium™ in Orlando, Florida, 10–13 February 2020. Freeline data has been selected for two oral presentations and associated posters at the conference.

Freeline appoints Theresa Heggie as Chief Executive

- A biopharma executive with significant experience in commercialisation of treatments for rare diseases joining Freeline after senior roles at leading global rare disease companies including Alnylam and Shire -

Lorenz Mayr Appointed as Entrepreneur in Residence

Syncona Ltd, a leading healthcare company focused on founding, building and funding global leaders in life sciences, announces the appointment of Lorenz Mayr, Ph.D. as Entrepreneur in Residence, from 1 January 2020. In this role, he will have a particular focus on sourcing new Syncona companies, developing and driving portfolio company business plans and strategy.